ABSTRACT
Objective To evaluate the long-term follow-up efficacy of intravitreal injection of anti-VEGF medication for choroidal neovascularization (CNV) caused by angioid streak.Methods A retrospective observational study was conducted in 21 patients (30 eyes) diagnosed as subfoveal CNV caused by angioid streak.Demographic data,clinical course,visual acuity,and findings of fluorescein angiography and optical coherence tomography (OCT) were evaluated and observed at least 3 years after antiVEGF treatment.Results Of all patients,the number of anti-VEGF injections was 6 to 18,with the average of 10 ±2.4,and the follow-up duration was 36 to 54 months,an average of (39.5 ± 2.2) months.Moreover,the mean best corrected visual acuity (BCVA) at the baseline was (31.0 ±3.81) characters,and the mean BCVA was (34.0 s0.35) characters at the final follow-up,and the total difference was not statistically significant (P =0.600).The baseline central retinal thickness (CRT) was (406.21 ± 21.23) im and (251.16 +36.36) μn at the end of the follow-up,and the difference of CRT before and after the treatment was statistically significant (P =0.002).Visual acuity of 16 eyes in 30 eyes was significantly improved after the initial treatment,but decreased to the baseline level in the follow-up because of CNV recurrence,10 eyes occurred varying degrees of macular atrophy and scarring changes,and there was no significant difference between visual acuity of the follow-up and the baseline (all P ＞0.05),and 4 eyes had stable CNV during the follow-up because the initial CNV did not involve the macular area.Conclusion The long-term outcomes of anti-VEGF treatment for choroidal neovascularization secondary to angioid streaks is not satisfactory due to its high recurrence and activity.
ABSTRACT
Objective To evaluate the long-term follow-up efficacy of intravitreal injection of anti-VEGF medication for choroidal neovascularization (CNV) caused by angioid streak.Methods A retrospective observational study was conducted in 21 patients (30 eyes) diagnosed as subfoveal CNV caused by angioid streak.Demographic data,clinical course,visual acuity,and findings of fluorescein angiography and optical coherence tomography (OCT) were evaluated and observed at least 3 years after antiVEGF treatment.Results Of all patients,the number of anti-VEGF injections was 6 to 18,with the average of 10 ±2.4,and the follow-up duration was 36 to 54 months,an average of (39.5 ± 2.2) months.Moreover,the mean best corrected visual acuity (BCVA) at the baseline was (31.0 ±3.81) characters,and the mean BCVA was (34.0 s0.35) characters at the final follow-up,and the total difference was not statistically significant (P =0.600).The baseline central retinal thickness (CRT) was (406.21 ± 21.23) im and (251.16 +36.36) μn at the end of the follow-up,and the difference of CRT before and after the treatment was statistically significant (P =0.002).Visual acuity of 16 eyes in 30 eyes was significantly improved after the initial treatment,but decreased to the baseline level in the follow-up because of CNV recurrence,10 eyes occurred varying degrees of macular atrophy and scarring changes,and there was no significant difference between visual acuity of the follow-up and the baseline (all P ＞0.05),and 4 eyes had stable CNV during the follow-up because the initial CNV did not involve the macular area.Conclusion The long-term outcomes of anti-VEGF treatment for choroidal neovascularization secondary to angioid streaks is not satisfactory due to its high recurrence and activity.